Clinical Trial Update: Beta3 Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the beta-3 adrenergic agonist mirabegron for chronic pulmonary hypertension secondary to heart failure.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Pulmonary Hypertension

Drugs mentioned

• Mirabegron (mirabegron)

Snippet

Sponsor: Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III | Conditions: Pulmonary Hypertension, Mirabegron | Phase 2 | Status: UNKNOWN